|
Home | Your Profile | Search | About Us | Pricing | Disclaimer |
|
|
| |
Home | |
|
Outsourcing Reports | |
|
Outsourcing Showcase | |
|
Reports Store | |
|
Outsourcing Directory | |
|
Events | |
|
Advertising | |
|
News | |
| | Help |
12 Items, CDN $ 11220 |
Go Back ![]() |
|||
Abstract 60 Pages "The Russian Clinical trials market has always enjoyed good returns since its inception, but its growth has been especially significant over the past few years, and is expected to post major growth in the future says our new report “Clinical Trials Market in Russia”. The number of Clinical trials conducted in Russia increased to 615 in 2008, which is an increase of around 9% over 2007. The country has a highly centralized healthcare system. It implies that the country has highly specialized medical units that deliver healthcare services to all the patients with common symptoms under one roof. The patients normally follow the references for the tests and treatments given by the doctors. These references are to the highly specialized doctors in the big hospitals. The Russian Clinical Trials have been enjoying significant foreign investments and accounts for more than two-third of the total clinical trials across the world. Russia sponsored 201 clinical trials in 2008, followed by American sponsors who conducted 145 clinical trials during the year. The clinical trials conducted by Russia include various therapy areas such as oncology, cardiology, pulmonology, etc. The country has large number of physicians who are willing to work as Clinical Research Investigators, to enhance their knowledge in their fields of specialization and earn a subsidiary income. The government is also taking vital steps to bring healthcare reforms and to encourage the Russian drug makers having well-laid plans for the development of innovative drugs, especially vaccines to compete in the market at par with the foreign players. It has recently invested US$ 3.4 Billion to improve the utilization of resources in the Russian Clinical Trials Market. Our report is the outcome of the extensive research and thorough analysis of the Russia Clinical Trials Market. It covers the various market dynamics that play upon the performance of the Russia Clinical Trials Market. The report will also help the client to assess the future outlook of the industry based on the government initiatives, regulatory framework and the growth pattern of the pharmaceutical industry." Table of Contents "1. Analyst View 2. Clinical Trials Market Overview 3. Russian Clinical Trials Market 3.1 Foreign Participation 3.2 Clinical Research Outsourcing 4. Market Performance and Forecast 4.1 Clinical Trials 4.2 Global Clinical Trial Study 4.3 Trials in Advanced Phases 4.4 Trials under Major Therapy Areas 4.5 Multi-national Sponsors 5. Patient Enrolment 5.1 Population 5.2 Disease Profile 5.3 Patient Recruitment 5.4 Patient Recruitment Rate 6. Regulatory Environment 7. Cost Analysis 7.1 Lab Fees 7.2 Hourly Rate of CRO 8. Clinical Trials and New Drugs Approval 8.1 FDA Inspections 8.2 FDA Approved Drugs 8.3 EMEA Approved Drugs 9. Key Market Trends 10. Industry Restraints 11. Key Players 11.1 Biocad 11.2 Novartis 11.3 Sanofi-Aventis 11.4 GlaxoSmithKline plc (GSK) 11.5 Pfizer" | |||
Using the Site Privacy & Security Statement
Advertise with us Directory Guide
CanBiotech Newsletters
© 2000-2010 CanBiotech™ Inc.